DAMORA THERAPEUTICS, INC. Payments for Restructuring
DAMORA THERAPEUTICS, INC. (DMRA) reported Payments for Restructuring of $2.70 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-03-19
- DAMORA THERAPEUTICS, INC. payments for restructuring for the quarter ending 2024-12-31 was $230.00K.
- DAMORA THERAPEUTICS, INC. payments for restructuring for the quarter ending 2024-09-30 was $590.00K.
- DAMORA THERAPEUTICS, INC. payments for restructuring for the quarter ending 2024-06-30 was $633.00K.
- DAMORA THERAPEUTICS, INC. payments for restructuring for the quarter ending 2024-03-31 was $1.25M.
- DAMORA THERAPEUTICS, INC. payments for restructuring for fiscal 2024 was $2.70M, a 69.62% increase from fiscal 2023.
- DAMORA THERAPEUTICS, INC. payments for restructuring for fiscal 2023 was $1.59M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2024-12-31 | $230.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $820.00K derived: sum of 2 quarters · filed 2026-03-19 | $1.45M derived: sum of 3 quarters · filed 2026-03-19 | $2.70M 10-K · filed 2026-03-19 |
| 2024-09-30 | $590.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $1.22M derived: sum of 2 quarters · filed 2024-11-01 | $2.47M 10-Q · filed 2024-11-01 | |
| 2024-06-30 | $633.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.88M 10-Q · filed 2024-08-12 | ||
| 2024-03-31 | $1.25M 10-Q · filed 2024-04-29 | |||
| 2023-12-31 | $1.59M 10-K · filed 2025-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |